Strain Name
|
NOD.CB17-PrkdcscidIl2rgtm1BcgenB2mtm1(B2M/HLA-A2.1)BcgenFcgrttm1(B2m/Fcgrt)Bcgen/Bcgen
|
Common Name
|
B-NDG hB2M/HLA-A2.1 mice plus
|
Background
|
B-NDG mice
|
Catalog number
|
112449
|
Aliases
|
B2m: Ly-m11, beta2-m, beta2m
HLA-A: HLAA
Fcgrt : Fc receptor, IgG, alpha chain transporter,as known as Fcrn
|
Determination of plasma concentrations of human IgG in different mice
Pharmacokinetic characteristic of B-NDG hB2M/HLA-A2.1 mice plus has no difference compared with B-NDG mice. B-NDG mice, B-NDG HLA-A2.1 mice, B-NDG hB2M/HLA-A2.1 mice plus were treated with YH001 (anti-human CTLA4 antibody) (n=4). Blood samples were collected at different time point for the PK assay. The results showed that the PK results of B-NDG hB2M/HLA-A2.1 mice plus group was similar to that in B-NDG mice, and the drug concentration of B-NDG HLA-A2.1 mice group could not be measured at the time point 4 days later. Results indicated that when compared with B-NDG HLA-A2.1 mice, the B-NDG hB2M/HLA-A2.1 mice plus can significantly extend the half-life of antibody drugs in mice.